Logo Image
News
Media
All VideosMedical World NewsPodcastsWeekly RecapCure ConnectionsInsightsSpecial ReportNeurologyLive Peer ExchangeMedcastPeers & PerspectivesRoundtable DiscussionsShortsShows & Podcasts
Conferences
Conference CoverageConference Listing
CME/CE
More
Partners
Publications
NeurologyLiveBridging the GapsInternational Journal of MS Care
Resources
Expert AuthorsFDA NewsFeaturesFuture Leaders in NeurologyGiants of Multiple SclerosisInteractive ToolsJob BoardLive EventsNeurology ResourcesParkinsonism Practical GuideSponsoredThe G.L.O.B.Virtual Events

Subscribe

  • News
  • Media
  • Conferences
  • CME/CE
  • Partners
  • Publications
  • Resources
  • Subscribe
  • Dementia and Alzheimer Disease
  • Epilepsy
  • Genetic Disorders
  • Headache and Migraine
    • Migraine
  • MS and Demyelinating Disorders
    • NMOSD
    • Multiple Sclerosis
  • Movement Disorders
    • Parkinson Disease
    • Dyskinesia
    • Huntington Disease
  • Neuro-Oncology
  • Neuromuscular
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Muscular Dystrophy
    • Ataxia
    • Generalized Myasthenia Gravis
    • LEMS
  • Rare Diseases
  • Sleep Disorders
    • Narcolepsy
    • Excessive Daytime Sleepiness
    • Insomnia
  • Stroke
Spotlight -
Expert Authors|
FDA News|
Upcoming Live Events|
AANEM 2026|
ECTRIMS 2026|
CNS 2026|
WSC 2026|
Parkinsonism Practical Guide
Advertisement

J. David Spence MD, FRCPC, FAHA

Advertisement

Articles by J. David Spence MD, FRCPC, FAHA

Taking a New Look at Resistant Atherosclerosis

ByJ. David Spence MD, FRCPC, FAHA,Heidi Anne Duerr, MPH
July 12th 2017

The notion of “resistant atherosclerosis,” points to possible breakthroughs in research and treatment.

Advertisement

Latest Updated Articles

  • Taking a New Look at Resistant Atherosclerosis
    Taking a New Look at Resistant Atherosclerosis

    July 12th 2017



Advertisement
Advertisement

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

1

Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study

2

Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development

3

AL-S Pharma Details Planned Phase 3 Trial Design for AP-101 in ALS

4

NeuroVoices: Cindy Zadikoff, MD, MSc, on the FDA Approval of Tavapadon for Parkinson Disease

5

Recapping the 2026 STARS Conference and the Push for Interdisciplinary Stuttering Care: Gerald Maguire, MD

  • About Us
  • Advisory Board
  • Editorial
  • Contact Us
  • Advertise
  • Contact MJH LS
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
  • Patient Care Online
HCP Live Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us